Recurrent aphthous stomatitis (RAS) is one of the most common mucosal diseases in humans. It is characterized by recurrent and painful ulcerations of the oral mucous membranes. Its prevalence in the general population is estimated to vary from 5% to 66%, with a mean of 20% (1,2). The disease 
INTRODUCTION
occurs in men and women of all ages. The etiology of RAS is unknown, although some factors, such as infectious agents, stress, trauma, hormonal changes, nutritional deficiencies, food allergy, and systemic diseases, have been proposed (1, 2) .
Celiac disease (CD), also known as celiac sprue, is an immune-mediated enteropathy induced by dietary gluten that affects genetically predisposed individuals. While it was previously considered to be a childhood disease, recent reports suggest an increased incidence among adults (3) . CD may be observed in both sexes, but a female-to-male predominance of 7:1 has been noted in most studies (4) . Prevalence rates of 1:120 to 1:300 have been reported in Western Europe (5) (6) (7) . Recent epidemiological data have shown a prevalence of CD approaching 1% in the general population (8) . CD has been classified into four phenotypes: classic, atypical, silent, and latent forms. "Classic disease" describes patients with the features of intestinal malabsorption, including diarrhea, weight loss and abdominal bloating. "Atypical disease" is characterized by few or no gastrointestinal symptoms but comes to medical attention for other reasons such as anemia, osteoporosis or infertility. "Silent disease" refers to asymptomatic patients who have villous atrophy on biopsy. These patients do not manifest any gastrointestinal symptoms or atypical features of the disease. "Latent disease" represents patients with a previous diagnosis of CD that responded to a gluten-free diet and who retain a normal mucosal histology. It can also represent patients with currently normal intestinal mucosa on a gluten-containing diet who will subsequently develop CD (9) . The diagnosis of CD is based on positive serologic antibodies (antigliadin, antiendomysial and tissue transglutaminase), characteristic small intestinal mucosal abnormalities on histological examination, and clinical, serological and histological remission on a strict gluten-free diet (10) . Although gastrointestinal findings are the most prominent and well-known presentations of CD, approximately 50% of patients with CD present no gastrointestinal symptoms when they are initially diagnosed. Currently, some authors consider various types of oral cavity pathologies to be clinical manifestations of CD, like dental enamel defects, soft tissue lesions and RAS (3, 6, (11) (12) (13) (14) (15) (16) (17) (18) . In dermatology, although dermatitis herpetiformis is an autoimmune blistering disease that appears as a cutaneous manifestation of gluten intolerance (12) , the association between CD and RAS has been long suspected and has been evaluated in several studies, but conflicting results have been reported.
In the present study, we aimed to determine the relationship between RAS and CD/gastrointestinal symptoms using serologic and histopathological tests.
MATERIALS AND METHODS
This was a prospective, controlled study. The study protocol was carried out in accordance with good clinical practices and the Declaration of Helsinki, as agreed to in 1975 and revised in 1983. All patients signed approved informed consent forms before enrollment in the study.
Study Population
Eighty-two patients consecutively referred to the Haydarpasa Numune Education and Research Hospital Dermatology Outpatient Clinic for the management of RAS between March 2007 and March 2009 were recruited into the RAS group. Additionally, a total of 82 consecutive outpatients who were scheduled for elective esophagogastroduodenoscopy (EGD) to investigate their dyspeptic complaints and who had no history of aphthous stomatitis or any other skin manifestation compatible with CD were recruited into the control group.
Patients who met any of the following criteria were excluded: (1) age younger than 18 years; (2) presence of Behçet's or inflammatory bowel diseases; (3) presence of clinically significant associated conditions such as hepatic, cardiorespiratory or renal disease, neoplastic diseases, or coagulopathy; or (4) pregnancy or breast-feeding.
Study Design
The diagnosis of RAS was performed by one dermatologist according to the history and physical examination based on accepted criteria. It was divided based on the clinical features of RAS: major ((larger than 1 cm and deeper than minor RAS and healing within 10 to 30 days), minor (less than 1 cm in diameter and healing within 4 to 14 days) and herpetiform aphthae (grouped aphthae, 1 to 2 mm in size and painful). All of the patients were asked to complete a questionnaire regarding their gastrointestinal symptoms.
All of the patients eligible for the study underwent EGD with conscious sedation. Prior to EGD, fasting venous plasma samples were taken from all patients for antibodies to gliadin IgA and IgG and to endomysium IgA and IgG. Serum IgA levels were also measured to rule out IgA deficiency. IgA and IgG antibodies to gliadin were assessed by ELISA (Euroimmun, Lubeck, Germany), and IgA and IgG antibodies to endomysium were assessed by an indirect immunofluorescence method (Euroimmun, Lubeck, Germany). To ensure consistency of the evaluation, all of the EGD examinations were performed by the same attending endoscopist using the Pentax EG-2970K videogastroscope (Asahi Optical, Tokyo, Japan). From all of the patients, a total of four biopsy specimens were taken from the distal part of the duodenum, and the biopsy specimens were fixed in a 10% formalin solution. All of the preparations were stained with hematoxylin-eosin for microscopic examination of the duodenal mucosa and were evaluated according to the Marsh classification by a single experienced pathologist, who was blinded to the results of the serologic tests that assessed CD status. Following these tests, cases with at least one positive serologic test with abnormal duodenal biopsy compatible with CD were defined as CD.
Statistical Analysis
Statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) version 11.5 statistical software (SPSS Inc., Chicago, IL, USA). The chi-square and Fisher's exact chi-square tests were used for comparison of the qualitative data. The results were evaluated at a 95% confidence interval and at a significance level of p<0.05.
RESULTS
Clinical features of RAS were detected as minor in 44 (53.7%), major in 31 (37.8%) and herpetiform in 7 (8.5%) in the buccal mucosa, labial mucosa and tongue. The RAS and control groups included 82 patients each, and there were no statistically significant differences between the groups with respect to age and gender (p=0.66, p=1.00, respectively). Pathologic examination of the duodenal biopsies revealed CD (Marsh IIIC) in only one patient in the RAS group, whereas none of the patients in the control group was positive for CD ( Table 1 ).
The following gastrointestinal symptoms were evaluated in the two groups: epigastric pain, chronic diarrhea, steatorrhea, abdominal distension/bloating, regurgitation, and weight loss. Reflux-like symptoms such as regurgitation and retrosternal heartburn were significantly higher in the RAS group (p<0.001 and p<0.001, respectively) ( Table 2) .
RAS group
Placebo group p-value (n = 82) (n = 82) 
DISCUSSION
Recurrent aphthous stomatitis (RAS) is characterized by painful ulcers that recur at intervals of a few days to up to 2-3 months. The peak of onset is during childhood, and it decreases in severity and frequency with age (1). Despite detailed study, the etiology of RAS is still unknown, but many predisposing factors, including trauma, stress, smoking cessation, hormonal imbalance, and food hypersensitivity, have been proposed (1,2). There is also strong evidence from histopathological studies that T-cell-mediated immune responses are associated with RAS (1,2). (Table 3) . Rose et al. (24) and O'Farrelly et al. (25) reported that it was unnecessary to perform jejunal biopsy in patients with RAS. In our study group, which included 82 patients, 3 (3.6%) were AGA IgG positive and 2 (2.4%) were AGA IgA positive, whereas in the control group that included the same number of patients, 1 (1.2%) was AGA IgG and AGA IgA positive. EMA IgA and IgG were only positive in 1 patient in the RAS group. In duodenal biopsies of the antibodypositive patients in both the RAS and control groups, only 1 (1.2%) patient was diagnosed as having CD in the RAS group, even though the patient was free of typical clinical symptoms of this disease. There were no statistically significant differences between the groups. Both EMA and AGA were positive in this patient. On the basis of these findings, it appears that the prevalence of CD in the RAS population does not significantly differ from that of the unaffected matched population.
We know that almost 50% of recently diagnosed celiac patients do not present with classical gastrointestinal symptoms (26) . In our study, there were no statistically significant differences between the gastrointestinal symptoms of the groups, which is consistent with the literature. However, retrosternal heartburn and regurgitation were higher in the RAS group (80.5%), and the difference was statistically significant (p<0.05). Although
